Phase 2 trial of BMS-986489, atigotatug (anti-fucosyl-GM1 monoclonal antibody) plus PD-1 inhibitor, in SCLC consolidation

An open-label randomized study compares the fixed-dose combination of atigotatug and nivolumab (BMS-986489) with standard durvalumab consolidation following chemoradiotherapy in limited-stage small-cell lung cancer. Sponsored by SCRI Development Innovations, LLC, the trial evaluates efficacy and safety in approximately 250 participants, exploring a novel immunotherapy approach.